China’s Sinopharm, Sinovac Covid-19 vaccines assessed by WHO for emergency use

China’s Sinopharm, Sinovac Covid-19 vaccines assessed by WHO for emergency use

Coronavirus vaccines developed by Chinese firms Sinovac and Sinopharm are being reviewed for emergency use by the World Health Organization, potentially opening the door to their increased international acceptance.

The UN agency is also in contact with another Chinese vaccine developer, CanSino, whose jab is undergoing phase 3 trials, it said.

The WHO’s advisory group makes recommendations about whether, how and for whom vaccines should be used. Its “emergency use listing” procedure allows unlicensed vaccines and treatments to be assessed to potentially expedite their approval by individual countries or jurisdictions in public health emergencies.

A decision on the Chinese vaccines was not expected until March at the earliest, the agency said.